A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Kjell Oberg, Eric P. Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Margot Tesselaar, Valentina Ambrosini, Richard P. Baum, Matthew H. Kulke, Marianne Pavel, Jaroslaw Cwikla, Ignat Drozdov, Massimo Falconi, Nicola Fazio, Andrea Frilling, Robert T. Jensen, Klaus Koopmans, Tiny Korse, Dik Kwekkeboom, Helmut R. MaeckeGiovanni Paganelli, Ramon Salazar, Stefano Severi, Jonathan R. Strosberg, Vikas Prasad, Aldo Scarpa, Ashley Grossman, Annemeik Walenkamp, Mauro Cives, Irene Virgolini, Andreas Kjaer, Irvin M. Modlin

Research output: Contribution to journalArticle

Abstract

The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

Original languageEnglish
Pages (from-to)174-87
Number of pages14
JournalEndocrine Connections
Volume5
Issue number5
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Disease Management
Biomarkers
Neoplasms
Chromogranin A
Messenger RNA
Phosphopyruvate Hydratase
Gastro-enteropancreatic neuroendocrine tumor
Serotonin
Therapeutics
RNA
Sensitivity and Specificity
Equipment and Supplies

Keywords

  • Journal Article

Cite this

Oberg, K., Krenning, E. P., Sundin, A., Bodei, L., Kidd, M., Tesselaar, M., ... Modlin, I. M. (2016). A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 5(5), 174-87. https://doi.org/10.1530/EC-16-0043

A Delphic consensus assessment : imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. / Oberg, Kjell; Krenning, Eric P.; Sundin, Anders; Bodei, Lisa; Kidd, Mark; Tesselaar, Margot; Ambrosini, Valentina; Baum, Richard P.; Kulke, Matthew H.; Pavel, Marianne; Cwikla, Jaroslaw; Drozdov, Ignat; Falconi, Massimo; Fazio, Nicola; Frilling, Andrea; Jensen, Robert T.; Koopmans, Klaus; Korse, Tiny; Kwekkeboom, Dik; Maecke, Helmut R.; Paganelli, Giovanni; Salazar, Ramon; Severi, Stefano; Strosberg, Jonathan R.; Prasad, Vikas; Scarpa, Aldo; Grossman, Ashley; Walenkamp, Annemeik; Cives, Mauro; Virgolini, Irene; Kjaer, Andreas; Modlin, Irvin M.

In: Endocrine Connections, Vol. 5, No. 5, 09.2016, p. 174-87.

Research output: Contribution to journalArticle

Oberg, K, Krenning, EP, Sundin, A, Bodei, L, Kidd, M, Tesselaar, M, Ambrosini, V, Baum, RP, Kulke, MH, Pavel, M, Cwikla, J, Drozdov, I, Falconi, M, Fazio, N, Frilling, A, Jensen, RT, Koopmans, K, Korse, T, Kwekkeboom, D, Maecke, HR, Paganelli, G, Salazar, R, Severi, S, Strosberg, JR, Prasad, V, Scarpa, A, Grossman, A, Walenkamp, A, Cives, M, Virgolini, I, Kjaer, A & Modlin, IM 2016, 'A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management', Endocrine Connections, vol. 5, no. 5, pp. 174-87. https://doi.org/10.1530/EC-16-0043
Oberg, Kjell ; Krenning, Eric P. ; Sundin, Anders ; Bodei, Lisa ; Kidd, Mark ; Tesselaar, Margot ; Ambrosini, Valentina ; Baum, Richard P. ; Kulke, Matthew H. ; Pavel, Marianne ; Cwikla, Jaroslaw ; Drozdov, Ignat ; Falconi, Massimo ; Fazio, Nicola ; Frilling, Andrea ; Jensen, Robert T. ; Koopmans, Klaus ; Korse, Tiny ; Kwekkeboom, Dik ; Maecke, Helmut R. ; Paganelli, Giovanni ; Salazar, Ramon ; Severi, Stefano ; Strosberg, Jonathan R. ; Prasad, Vikas ; Scarpa, Aldo ; Grossman, Ashley ; Walenkamp, Annemeik ; Cives, Mauro ; Virgolini, Irene ; Kjaer, Andreas ; Modlin, Irvin M. / A Delphic consensus assessment : imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. In: Endocrine Connections. 2016 ; Vol. 5, No. 5. pp. 174-87.
@article{4fb4e086c813491c899946173ff5542a,
title = "A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management",
abstract = "The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75{\%}) was achieved for 78{\%} of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.",
keywords = "Journal Article",
author = "Kjell Oberg and Krenning, {Eric P.} and Anders Sundin and Lisa Bodei and Mark Kidd and Margot Tesselaar and Valentina Ambrosini and Baum, {Richard P.} and Kulke, {Matthew H.} and Marianne Pavel and Jaroslaw Cwikla and Ignat Drozdov and Massimo Falconi and Nicola Fazio and Andrea Frilling and Jensen, {Robert T.} and Klaus Koopmans and Tiny Korse and Dik Kwekkeboom and Maecke, {Helmut R.} and Giovanni Paganelli and Ramon Salazar and Stefano Severi and Strosberg, {Jonathan R.} and Vikas Prasad and Aldo Scarpa and Ashley Grossman and Annemeik Walenkamp and Mauro Cives and Irene Virgolini and Andreas Kjaer and Modlin, {Irvin M.}",
note = "{\circledC} 2016 The authors.",
year = "2016",
month = "9",
doi = "10.1530/EC-16-0043",
language = "English",
volume = "5",
pages = "174--87",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "5",

}

TY - JOUR

T1 - A Delphic consensus assessment

T2 - imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

AU - Oberg, Kjell

AU - Krenning, Eric P.

AU - Sundin, Anders

AU - Bodei, Lisa

AU - Kidd, Mark

AU - Tesselaar, Margot

AU - Ambrosini, Valentina

AU - Baum, Richard P.

AU - Kulke, Matthew H.

AU - Pavel, Marianne

AU - Cwikla, Jaroslaw

AU - Drozdov, Ignat

AU - Falconi, Massimo

AU - Fazio, Nicola

AU - Frilling, Andrea

AU - Jensen, Robert T.

AU - Koopmans, Klaus

AU - Korse, Tiny

AU - Kwekkeboom, Dik

AU - Maecke, Helmut R.

AU - Paganelli, Giovanni

AU - Salazar, Ramon

AU - Severi, Stefano

AU - Strosberg, Jonathan R.

AU - Prasad, Vikas

AU - Scarpa, Aldo

AU - Grossman, Ashley

AU - Walenkamp, Annemeik

AU - Cives, Mauro

AU - Virgolini, Irene

AU - Kjaer, Andreas

AU - Modlin, Irvin M.

N1 - © 2016 The authors.

PY - 2016/9

Y1 - 2016/9

N2 - The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

AB - The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.

KW - Journal Article

U2 - 10.1530/EC-16-0043

DO - 10.1530/EC-16-0043

M3 - Article

C2 - 27582247

VL - 5

SP - 174

EP - 187

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 5

ER -